These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 33964007)

  • 41. Pathogenesis of Graves' orbitopathy: a 2010 update.
    Smith TJ
    J Endocrinol Invest; 2010 Jun; 33(6):414-21. PubMed ID: 20631493
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Worsening of Graves' ophthalmopathy after SARS-CoV-2 mRNA vaccination.
    Patrizio A; Ferrari SM; Antonelli A; Fallahi P
    Autoimmun Rev; 2022 Jul; 21(7):103096. PubMed ID: 35413468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review.
    Mohamed A; Tzoulis P; Kossler AL; Dosiou C
    J Clin Endocrinol Metab; 2023 Mar; 108(4):979-985. PubMed ID: 36251747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease.
    Lazarus JH
    Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):273-9. PubMed ID: 22632364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Editorial: News in Graves' orbitopathy: patients management and treatments.
    Lanzolla G; Sabini E
    Front Endocrinol (Lausanne); 2023; 14():1270467. PubMed ID: 37664861
    [No Abstract]   [Full Text] [Related]  

  • 47. Euthyroid Graves' ophthalmopathy with negative autoantibodies.
    Cakir M
    J Natl Med Assoc; 2005 Nov; 97(11):1547-9. PubMed ID: 16334503
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Animal models of Graves' disease and Graves' orbitopathy.
    Nagayama Y; Nakahara M; Abiru N
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):381-6. PubMed ID: 26181432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities.
    Bifulco M; Ciaglia E
    Endocrine; 2016 Sep; 53(3):649-50. PubMed ID: 26438397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves' disease and Graves' ophthalmopathy.
    Bufalo NE; Dos Santos RB; Marcello MA; Piai RP; Secolin R; Romaldini JH; Ward LS
    J Endocrinol Invest; 2015 May; 38(5):555-61. PubMed ID: 25543543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A case of carotid cavernous fistula mimicking Graves' orbitopathy.
    Cosentino G; Comi S; Maglionico MN; Marinò M
    J Endocrinol Invest; 2024 Jan; 47(1):255-256. PubMed ID: 37347382
    [No Abstract]   [Full Text] [Related]  

  • 52. SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves' disease.
    Murugan AK; Alzahrani AS
    Endocrine; 2021 Aug; 73(2):243-254. PubMed ID: 34106438
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal management of Graves orbitopathy: a multidisciplinary approach.
    Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
    Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Graves' disease following administration of second dose of SARS-CoV-2 vaccine.
    Goblirsch TJ; Paulson AE; Tashko G; Mekonnen AJ
    BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34969799
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel treatment modalities for Graves' orbitopathy.
    Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The tale of radioiodine and Graves' orbitopathy.
    Ponto KA; Zang S; Kahaly GJ
    Thyroid; 2010 Jul; 20(7):785-93. PubMed ID: 20578895
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features.
    Gopinath B; Musselman R; Adams CL; Tani J; Beard N; Wall JR
    Thyroid; 2006 Oct; 16(10):967-74. PubMed ID: 17042681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
    Wiersinga WM
    J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.
    Yin X; Latif R; Bahn R; Tomer Y; Davies TF
    Thyroid; 2008 Nov; 18(11):1201-6. PubMed ID: 18925838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.